A Phase 3 interventional study of Daclatasvir and Sofosbuvir in Hepatitis C, sponsored by Bristol-Myers Squibb. Completed at 10 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-01-27.
Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 59 studies testing daclatasvir in Hepatitis C — 1 open to participants now, 2 under way, 1 of them phase 3. daclatasvir · Hepatitis C.
Among the 59 studies testing daclatasvir in Hepatitis C, this one is the 39th largest by enrollment, is one of 9 that started in 2015, is one of 24 in phase 3, and was the 42nd registered.
1,744 studies on the registry are indexed under Hepatitis C; 98 are open to participants now.
Browse Hepatitis C studies →1 of the 59 studies testing daclatasvir in Hepatitis C is open now, in 1 country. Recruiting first, the newest first:
Tanta University · Sites in Egypt
Ages 18+
By country, each count listing its studies:
daclatasvir: first FDA approval 2015 (DAKLINZA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 56 Hepatitis C studies recruiting now, 43 (77%) set no upper age limit and 6 (11%) stop at 75 or younger; 10 take children under 18; 26 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
59 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 18 · Phase 3 25 · Phase 4 5
First in 2009; this study’s year is marked. 9 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 53 is below the median of 73 across 1,224 interventional studies indexed under Hepatitis C.
Median enrollment 100 across the 59 interventional studies. Of the 53 that completed or were terminated, 25 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
44 of 59 have an industry lead sponsor. The 10 most frequent:
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
78 studies in Hepatitis C by Bristol-Myers Squibb: none open now, none under way, none of them phase 3. Of 70 finished, 25 (36%) have results posted.
Among the 78 studies in Hepatitis C by Bristol-Myers Squibb, this one is the 41st largest by enrollment of the 67 interventional ones that give a count, is one of 8 that started in 2015, is one of 26 in phase 3, and was the 65th registered.
Bristol-Myers Squibb’s Hepatitis C studies by the year they started, since 2007.
None of the studies under way reaches primary completion within a year.
Among the 59 studies testing daclatasvir in Hepatitis C, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Bristol-Myers Squibb’s 78 in Hepatitis C:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to determine if the combination of Daclatasvir, Sofosbuvir and Ribavirin for 12 or 16 weeks is safe and effective in the treatment of Genotype 3 Chronic Hepatitis C (HCV) in patients with advanced fibrosis or compensated cirrhosis. Patients in this study may have already been treated prior for HCV or may have never received treatment for their HCV.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com
Inclusion Criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Oral dosing Daclatasvir 60mg once daily, Sofosbuvir 400mg once daily, and Ribavirin 1000-1200mg (weight based dosing) split into am and pm dosing
Drug: Daclatasvir · Drug: Sofosbuvir · Drug: Ribavirin
Oral dosing Daclatasvir 60mg once daily, Sofosbuvir 400mg once daily, and Ribavirin 1000-1200mg (weight based dosing) split into am and pm dosing
Drug: Daclatasvir · Drug: Sofosbuvir · Drug: Ribavirin
Percent of Participants With a Sustained Virologic Response (SVR) at Follow-up Week 12 (SVR12)
SVR12, defined as percentage of participants with hepatitis C virus (HCV) ribonucleic acid (RNA) \< lower limit of quantitation (LLOQ), target detected (TD) or target not detected (TND) at follow-up Week 12. SVR12 imputation was based on Next Value Carried Backwards (NVCB) approach. HCV RNA measurements were excluded after the start of non-study anti-HCV medication on treatment or during follow-up.
Time frame: Follow-up Week 12
Percent of Participants With a Sustained Virologic Response (SVR) at Follow-up Week 4 (SVR4) and Follow-up Week 24 (SVR24)
SVR4, defined as percentage of participants with hepatitis C virus (HCV) ribonucleic acid (RNA) \< lower limit of quantitation (LLOQ), target detected (TD) or target not detected (TND) at follow-up Week 4. SVR24, defined as percentage of participants with hepatitis C virus (HCV) ribonucleic acid (RNA) \< lower limit of quantitation (LLOQ), target detected (TD) or target not detected (TND) at follow-up Week 24. SVR4 imputation was based on Next Value Carried Backwards (NVCB) approach. SVR24 imputation was based on missing being treated as non-responder. HCV RNA measurements were excluded after the start of non-study anti-HCV medication on treatment or during follow-up.
Time frame: Follow-up Weeks 4 and 24
Number of Participants With Death, Serious Adverse Events (SAEs), Discontinuation Due to Adverse Events (AEs), Grade 3 or Grade 4 (Grade 3/4) AEs, and Grade 3/4 Laboratory Abnormalities
Serious adverse event (SAE) defined: a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Adverse event (AE) defined: any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. The degree of the adverse event or laboratory abnormality are evaluated by grades: Grade (Gr) 1=Mild, Gr 2=Moderate, Gr 3=Severe, Gr 4=Life-threatening or disabling, Gr 5=Death. Grading as per using National Cancer Institute Common Terminology Criteria (NCI CTC) Version 3.0 criteria.
Time frame: Date of First Dose of Study Drug to 7 Days post last dose of study drug (up to 13 weeks or 17 weeks depending on the randomized treatment group)
53 participants were enrolled. 50 participants were randomized and treated (24 to 12 week arm, 26 to 16 week arm). Reason for non-randomization was 3 no longer met study criteria.
| Milestone | Daclatasvir + Sofosbuvir + Ribavirin (12 Weeks) | Daclatasvir + Sofosbuvir + Ribavirin (16 Weeks) |
|---|---|---|
| Started | 24 | 26 |
| Completed | 23 | 26 |
| Not completed | 1 | 0 |
| Withdrew: Death | 1 | 0 |
| Milestone | Daclatasvir + Sofosbuvir + Ribavirin (12 Weeks) | Daclatasvir + Sofosbuvir + Ribavirin (16 Weeks) |
|---|---|---|
| Started | 23 | 26 |
| Completed | 23 | 26 |
| Not completed | 0 | 0 |
SVR12, defined as percentage of participants with hepatitis C virus (HCV) ribonucleic acid (RNA) \< lower limit of quantitation (LLOQ), target detected (TD) or target not detected (TND) at follow-up Week 12. SVR12 imputation was based on Next Value Carried Backwards (NVCB) approach. HCV RNA measurements were excluded after the start of non-study anti-HCV medication on treatment or during follow-up.
| percentage of participants | Daclatasvir + Sofosbuvir + Ribavirin (12 Weeks) | Daclatasvir + Sofosbuvir + Ribavirin (16 Weeks) |
|---|---|---|
| Percent of Participants With a Sustained Virologic Response (SVR) at Follow-up Week 12 (SVR12) | 87.5 (67.6 to 97.3) | 92.3 (74.9 to 99.1) |
SVR4, defined as percentage of participants with hepatitis C virus (HCV) ribonucleic acid (RNA) \< lower limit of quantitation (LLOQ), target detected (TD) or target not detected (TND) at follow-up Week 4. SVR24, defined as percentage of participants with hepatitis C virus (HCV) ribonucleic acid (RNA) \< lower limit of quantitation (LLOQ), target detected (TD) or target not detected (TND) at follow-up Week 24. SVR4 imputation was based on Next Value Carried Backwards (NVCB) approach. SVR24 imputation was based on missing being treated as non-responder. HCV RNA measurements were excluded after the start of non-study anti-HCV medication on treatment or during follow-up.
| percentage of participants | Daclatasvir + Sofosbuvir + Ribavirin (12 Weeks) | Daclatasvir + Sofosbuvir + Ribavirin (16 Weeks) |
|---|---|---|
| Follow-up Week 4 (SVR4) | 87.5 (67.6 to 97.3) | 96.2 (80.4 to 99.9) |
| Follow-up Week 24 (SVR24) | 87.5 (67.6 to 97.3) | 92.3 (74.9 to 99.1) |
Serious adverse event (SAE) defined: a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Adverse event (AE) defined: any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. The degree of the adverse event or laboratory abnormality are evaluated by grades: Grade (Gr) 1=Mild, Gr 2=Moderate, Gr 3=Severe, Gr 4=Life-threatening or disabling, Gr 5=Death. Grading as per using National Cancer Institute Common Terminology Criteria (NCI CTC) Version 3.0 criteria.
| participants | Daclatasvir + Sofosbuvir + Ribavirin (12 Weeks) | Daclatasvir + Sofosbuvir + Ribavirin (16 Weeks) |
|---|---|---|
| Death | 1 | 0 |
| SAEs | 2 | 3 |
| Discontinuation due to AEs | 0 | 0 |
| Grade 3/4 AEs | 2 | 2 |
| Grade 3/4 Laboratory Abnormalities | 1 | 2 |
Collected over SAEs were reported from date of first dose of study drug to 30 days post discontinuation of the last dose which was up to 16 weeks or 20 weeks depending on the randomized treatment group. Non-serious AEs were reported from date of first dose of study drug to 7 days post discontinuation of the last dose which was up to 13 weeks or 17 weeks depending on the randomized treatment group.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Daclatasvir + Sofosbuvir + Ribavirin (12 Weeks) | — | 2/24 (8.3%) | 21/24 (87.5%) |
| Daclatasvir + Sofosbuvir + Ribavirin (16 Weeks) | — | 3/26 (11.5%) | 22/26 (84.6%) |
| Event | Daclatasvir + Sofosbuvir + Ribavirin (12 Weeks) | Daclatasvir + Sofosbuvir + Ribavirin (16 Weeks) |
|---|---|---|
| SomnolenceNervous system disorders | 1/24 | 0/26 |
| Congestive cardiomyopathyCardiac disorders | 1/24 | 0/26 |
| ArteriosclerosisVascular disorders | 0/24 | 1/26 |
| PneumoniaInfections and infestations | 0/24 | 1/26 |
| Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/24 | 1/26 |
| Event | Daclatasvir + Sofosbuvir + Ribavirin (12 Weeks) | Daclatasvir + Sofosbuvir + Ribavirin (16 Weeks) |
|---|---|---|
| InsomniaPsychiatric disorders | 8/24 | 7/26 |
| HeadacheNervous system disorders | 7/24 | 5/26 |
| FatigueGeneral disorders | 6/24 | 7/26 |
| IrritabilityPsychiatric disorders | 5/24 | 2/26 |
| AstheniaGeneral disorders | 1/24 | 5/26 |
| DiarrhoeaGastrointestinal disorders | 1/24 | 4/26 |
| NauseaGastrointestinal disorders | 3/24 | 1/26 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 2/24 | 3/26 |
| Back painMusculoskeletal and connective tissue disorders | 0/24 | 3/26 |
| HypertensionVascular disorders | 0/24 | 3/26 |
Treated Population: All enrolled participants who received at least 1 dose of study drug
| Age, Continuous(years) | Daclatasvir + Sofosbuvir + Ribavirin (12 Weeks) | Daclatasvir + Sofosbuvir + Ribavirin (16 Weeks) | Total |
|---|---|---|---|
| Mean | 53.0 ± 7.77 | 55.0 ± 5.75 | 54.1 ± 6.80 |
| Age, Customized(participants) | Daclatasvir + Sofosbuvir + Ribavirin (12 Weeks) | Daclatasvir + Sofosbuvir + Ribavirin (16 Weeks) | Total |
|---|---|---|---|
| <65 | 23 | 26 | 49 |
| >=65 | 1 | 0 | 1 |
| Gender(Participants) | Daclatasvir + Sofosbuvir + Ribavirin (12 Weeks) | Daclatasvir + Sofosbuvir + Ribavirin (16 Weeks) | Total |
|---|---|---|---|
| Female | 6 | 4 | 10 |
| Male | 18 | 22 | 40 |
The record gives a start of Feb 2015, a primary completion of Oct 2015 and a completion of Dec 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2017, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Daclatasvir · Sofosbuvir · Ribavirin